X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
medicine, general & internal (9) 9
index medicus (8) 8
abridged index medicus (7) 7
aged (7) 7
cardiovascular disease (7) 7
double-blind method (7) 7
female (7) 7
humans (7) 7
male (7) 7
cardiovascular diseases (6) 6
clinical trials (6) 6
diabetes (6) 6
health risk assessment (6) 6
incidence (6) 6
middle aged (6) 6
myocardial infarction (6) 6
stroke (6) 6
cerebral infarction (5) 5
diabetes mellitus (5) 5
disease control (5) 5
heart attacks (5) 5
risk (5) 5
cardiovascular diseases - mortality (4) 4
cardiovascular diseases - prevention & control (4) 4
kaplan-meier estimate (4) 4
mortality (4) 4
myocardial infarction - prevention & control (4) 4
stroke - prevention & control (4) 4
acute coronary syndromes (3) 3
blood pressure (3) 3
care and treatment (3) 3
coronary artery disease (3) 3
diabetes mellitus, type 2 - complications (3) 3
diabetes mellitus, type 2 - drug therapy (3) 3
drug administration schedule (3) 3
drug therapy, combination (3) 3
follow-up studies (3) 3
glucagon (3) 3
glucagon-like peptide 1 (3) 3
health risks (3) 3
heart diseases (3) 3
hemoglobin (3) 3
metaanalysis (3) 3
motivation (3) 3
myocardial infarction - epidemiology (3) 3
patients (3) 3
peptides (3) 3
prevention (3) 3
randomization (3) 3
research (3) 3
therapy (3) 3
activating-factor acetylhydrolase (2) 2
agonists (2) 2
anticoagulants (2) 2
aspirin (2) 2
aspirin - administration & dosage (2) 2
aspirin - adverse effects (2) 2
aspirin - therapeutic use (2) 2
base-line (2) 2
benzaldehydes - adverse effects (2) 2
cancer (2) 2
cardiovascular diseases - epidemiology (2) 2
cardiovascular outcomes (2) 2
coronary artery disease - drug therapy (2) 2
coronary vessels (2) 2
creatinine (2) 2
disease (2) 2
disease prevention (2) 2
dose-response relationship, drug (2) 2
drug dosages (2) 2
drug testing (2) 2
drug therapy (2) 2
events (2) 2
factor xa inhibitors - administration & dosage (2) 2
factor xa inhibitors - adverse effects (2) 2
factor xa inhibitors - therapeutic use (2) 2
hemorrhage - chemically induced (2) 2
hypoglycemia (2) 2
hypoglycemic agents - therapeutic use (2) 2
kidney diseases (2) 2
kidneys (2) 2
lipoprotein (2) 2
management (2) 2
morbidity (2) 2
myocardial infarction - etiology (2) 2
outcomes (2) 2
oximes - adverse effects (2) 2
phospholipase a (2) 2
platelet aggregation inhibitors - administration & dosage (2) 2
platelet aggregation inhibitors - adverse effects (2) 2
platelet aggregation inhibitors - therapeutic use (2) 2
risk analysis (2) 2
risk factors (2) 2
rivaroxaban (2) 2
rivaroxaban - administration & dosage (2) 2
rivaroxaban - adverse effects (2) 2
rivaroxaban - therapeutic use (2) 2
safety (2) 2
stroke - epidemiology (2) 2
stroke - etiology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Hernandez, Adrian F and Green, Fiona and Green, Jennifer B and Janmohamed, Salim and D'Agostino, Ralph B and Granger, Christopher B and Jones, Michael and Jones, Nigel P and Leiter, Lawrence A and Rosenberg, Anne E and Rosenberg, Anne and Sigmon, Kristina and Sigmon, Kristina N and Somerville, Matthew and Somerville, Matthew C and Thorpe, Karl and Thorpe, Karl M and McMurray, John J V and McMurray, John J.V and Del Prato, Stefano and Califf, Robert M and Holman, Rury and DeMets, David and Riddle, Matthew and Goodman, Shaun and McGuire, Darren and Alexander, Karen and Devore, Adam and Melloni, Chiara and Patel, Chetan and Patel, Rajesh and Patel, Vickas and Patel, Prashant and Patel, Rajivkumar and Kong, David and Bloomfield, Gerald and Roe, Matthew and Tricoci, Pierluigi and Harrison, Rob and Harrison, Lindsay and Lopes, Renato and Mathews, Robin and Mehta, Anand and Mehta, Rajendra and Schuyler Jones, William and Vemulapalli, Sreekanth and Povsic, Thomas and Eapen, Zubin and Dombrowski, Keith and Kolls, Brad and Jordan, Dedrick and Ambrosy, Andrew and Greene, Deb and Greene, Stephen and Mandawat, Aditya and Shavadia, Jay and Cooper, John and Cooper, Lauren and Sharma, Abhinav and Sharma, Richa and Guimaraes, Patricia and Friedman, Daniel and Wilson, Matt and Wilson, Tim and Endsley, Patricia and Gentry, Tracy and Collier, Jeannie and Perez, Kathleen and James, Kourtnei and James, Rachel and Roush, Jennifer and Pope, Connie and Howell, Christina and Johnson, Megan and Johnson, David and Johnson, Andrew and Bailey, Matt and Cole, Joanna and Akers, Teresa and Vandyne, Beth and Thomas, Betsy and Rich, Jenny and Bartone, Susan and Beaulieu, Gail and Brown, Judith and Brown, Kim and Chau, Tuan and Christian, Tamra and Coker, Rebecca and Haddock, Trevorlyn and Jenkins, Wendy and Haque, Ghazala and Marquess, Marsha and Pesarchick, Jean and Rethaford, Renee and Stone, Allegra and Al Kawas, Firas and Anderson, Michelle and Enns, Robert and Sinay, Isaac and ... and Harmony Outcomes Comm Investigator and Harmony Outcomes committees and investigators
The Lancet, ISSN 0140-6736, 10/2018, Volume 392, Issue 10157, pp. 1519 - 1529
Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | METAANALYSIS | MELLITUS | SAFETY | RECEPTOR AGONISTS | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Glucagon-Like Peptide 1 - administration & dosage | Glucagon-Like Peptide 1 - analogs & derivatives | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Stroke - etiology | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Aged | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Myocardial Infarction - etiology | Diabetes Mellitus, Type 2 - complications | Glucagon-Like Peptide 1 - therapeutic use | Myocardial infarction | Diabetic retinopathy | Heart attacks | Peptides | Glucagon | Medical services | Clinical trials | Cardiovascular disease | Thyroid gland | Incidence | Thyroid carcinoma | Randomization | Motivation | Hemoglobin | Diuretics | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1 | Thyroid | Cerebral infarction | Stroke | Diabetes mellitus | Pancreatitis | Health risks | Risk reduction | Disease control | Patients | Organic chemistry | Interactive systems | Pancreatic cancer | Fatalities | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Diaz, Rafael and Widimsky, Peter and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Keltai, Katalin and Maggioni, Aldo P and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Pogosova, Nana and Ryden, Lars and Fox, Keith A A and Bhatt, Deepak L and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Avezum, Alvaro A and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ... and COMPASS Investigators
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Index Medicus | Abridged Index Medicus
Journal Article
by Connolly, Stuart J and Eikelboom, John W and Bosch, Jackie and Dagenais, Gilles and Dyal, Leanne and Lanas, Fernando and Metsarinne, Kaj and O'Donnell, Martin and Dans, Anthony L and Ha, Jong-Won and Parkhomenko, Alexandr N and Avezum, Alvaro A and Lonn, Eva and Lisheng, Liu and Torp-Pedersen, Christian and Widimsky, Petr and Maggioni, Aldo P and Felix, Camilo and Keltai, Katalin and Hori, Masatsugu and Yusoff, Khalid and Guzik, Tomasz J and Bhatt, Deepak L and Branch, Kelley R H and Cook Bruns, Nancy and Berkowitz, Scott D and Anand, Sonia S and Varigos, John D and Fox, Keith A A and Yusuf, Salim and SALA, JORGELINA and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and ZAIDMAN, CESAR and VOGEL, DANIEL and HRABAR, ADRIAN and SCHYGIEL, PABLO OMAR and CUNEO, CARLOS and LUQUEZ, HUGO and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and MONTANA, OSCAR and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and GARRIDO, MARCELO and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and DRAN, RICARDO DARIO and CARDONA, MARCELO and GUZMAN, RANDOLPH and GUZMAN, LUIS and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and NANI, SEBASTIAN and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and GONZALEZ COLASO, PATRICIA DEL CARMEN and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and ECTOR, BAVO and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and VRANCKX, PASCAL and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and INDIO DO BRASIL, CLARISSE and PRECOMA, DALTON and ABRANTES, JOSE ANTONIO and MANENTI, EULER and REIS, GILMAR and SARAIVA, JOSE and MAIA, LILIA and HERNANDES, MAURO and ROSSI, PAULO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and RECH, RAFAEL and ... and COMPASS Investigators and COMPASS investigators
The Lancet, ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | ORAL RIVAROXABAN | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2012, Volume 367, Issue 23, pp. 2204 - 2213
Patients with type 2 diabetes at high risk for cardiovascular disease who were already taking a renin–angiotensin system blocker were randomly assigned to the... 
GLOMERULAR-FILTRATION-RATE | CHRONIC HEART-FAILURE | MEDICINE, GENERAL & INTERNAL | CONVERTING-ENZYME INHIBITORS | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | DOUBLE-BLIND | CARDIOVASCULAR MORTALITY | FOLLOW-UP | SYSTOLIC DYSFUNCTION | BLOOD-PRESSURE | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Patient Dropouts | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Kidney Diseases - epidemiology | Treatment Failure | Amides - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Hypokalemia | Female | Drug Therapy, Combination | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Fumarates - therapeutic use | Kidney Diseases - prevention & control | Amides - therapeutic use | Fumarates - adverse effects | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Renin - antagonists & inhibitors | Hyperkalemia - chemically induced | Aged | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Angiotensin Receptor Antagonists - therapeutic use | Myocardial infarction | Women | Creatinine | Cerebral infarction | End-stage renal disease | Stroke | Heart attacks | Kidneys | Diabetes mellitus | Cardiovascular disease | Coronary artery disease | Hypotension | Hyperkalemia | Renin | Angiotensin | Renal failure | Diabetes | Kidney diseases | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Kidney transplantation | Index Medicus | Abridged Index Medicus
Journal Article